| Outcome Measures: |
Primary: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE), Bleeding related AEs include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically-relevant non major bleeding or major bleeding., Up to approximately 104 days|Number of Participants Who Experience One or More AEs, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention., Up to approximately 104 days|Number of Participants Who Discontinue Study Intervention Due to an AE, An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention., Up to approximately 8 days | Secondary: Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) of MK-2060, The AUC0-168 was defined as the area under the concentration-time curve of MK-2060 in plasma from time zero to 168 hours after administration. The Week 1 value is the extrapolated value using data up to 48 hours postdose Day 1, with the "Partial area" option in WinNonlin software using a Start time of 0 hours and an End time of 168 hours. Week 2 value included data for Day 8: predose, and 1, 12, 24, 48, 96, and 168 hours postdose., Day 1: predose, and 1, 12, 24, and 48 hours postdose. Day 8: predose, and 1, 12, 24, 48, 96, and 168 hours postdose.|Maximum Plasma Concentration (Cmax) of MK-2060, Cmax was defined as the maximum concentration of MK-2060 observed in plasma after administration. Week 2 value included data for Day 8: predose and 1, 12, 24, 48, 96, and 168 hours postdose., Day 1: predose, and 1, 12, and 48 hours postdose. Day 8: predose, and 1, 12, and 24 hours postdose; and once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.|Plasma Concentration at 168 Hours (C168) of MK-2060, C168 was defined as the concentration of MK-2060 observed in plasma 168 hours after administration. Week 2 value included data for Day 8: 168 hours postdose., Days 1 and 8: 168 hours post-dose|Time to Maximum Plasma Concentration (Tmax) of MK-2060, Tmax was defined as the time required to reach the maximum concentration of MK-2060 observed in plasma after administration. Week 2 value included data for Day 8: predose and 1, 12, 24, 48, 96, and 168 hours postdose., Day 1: predose, and 1, 12, and 48 hours postdose. Day 8: predose, and 1, 12, and 24 hours postdose; and once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.|Terminal Half Life (t1/2) of MK-2060, T1/2 was defined as the time required to divide the MK-2060 plasma concentration by two after reaching pseudo-equilibrium., Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.|Clearance at Steady State (CLss) of MK-2060, CLss was defined as the volume of plasma from which MK-2060 was eliminated per unit time following administration, once at steady state., Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.|Apparent Volume of Distribution at Steady State (Vss) of MK-2060, Vss was defined as the volume of plasma that would be necessary to contain the total amount of administered MK-2060 at the same concentration that MK-2060 was observed in the blood plasma after reaching steady state., Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.|Time to Hemostasis Following MK-2060 Treatment, Time to hemostasis is assessed by measuring the time that pressure is held from removal of dialysis catheters from the dialysis access site \[i.e., arteriovenous (AV) fistula or AV graft\] until adequate hemostasis has been obtained for both the arterial and venous sites., Up to approximately 15 days
|
